PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34527171-10	2021	As knockdown of Nrf2 reduced the metastatic and invasive ability of anaplastic thyroid cancer cells by inhibiting the Notch 1 signaling pathway and increased the cancer cell sensitivity to lenvatinib, Nrf2 could be a promising therapeutic target for patients with anaplastic thyroid cancer.	lenvatinib	189-199	NFE2 like bZIP transcription factor 2	Homo sapiens	201-205	
34527171-0	2021	The Knockdown of Nrf2 Suppressed Tumor Growth and Increased the Sensitivity to Lenvatinib in Anaplastic Thyroid Cancer.	lenvatinib	79-89	NFE2 like bZIP transcription factor 2	Homo sapiens	17-21	
34527171-5	2021	The impact of Nrf2 on the sensitivity of anaplastic thyroid cancer cells to lenvatinib was also investigated to evaluate its potential clinical implication.	lenvatinib	76-86	NFE2 like bZIP transcription factor 2	Homo sapiens	14-18	
34527171-9	2021	Lastly, knockdown of Nrf2 increased the sensitivity of anaplastic thyroid cancer cells to lenvatinib.	lenvatinib	90-100	NFE2 like bZIP transcription factor 2	Homo sapiens	21-25	
34527171-10	2021	As knockdown of Nrf2 reduced the metastatic and invasive ability of anaplastic thyroid cancer cells by inhibiting the Notch 1 signaling pathway and increased the cancer cell sensitivity to lenvatinib, Nrf2 could be a promising therapeutic target for patients with anaplastic thyroid cancer.	lenvatinib	189-199	NFE2 like bZIP transcription factor 2	Homo sapiens	16-20	
35466502-3	2022	However, the mechanism of lenvatinib-induced cytotoxicity and the relationships between lenvatinib resistance and Nrf2 are unclear.	lenvatinib	88-98	NFE2 like bZIP transcription factor 2	Homo sapiens	114-118	
35466502-4	2022	Thus, we investigated the relationship between lenvatinib and ferroptosis and clarified the involvement of Nrf2 in lenvatinib-induced cytotoxicity.Cell viability, lipid ROS levels, and protein expression were measured using Hep3B and HuH7 cells treated with lenvatinib or erastin.	lenvatinib	115-125	NFE2 like bZIP transcription factor 2	Homo sapiens	107-111	
35466502-10	2022	Nrf2-silenced HCC cells displayed sensitivity to lenvatinib and high lipid ROS levels.	lenvatinib	49-59	NFE2 like bZIP transcription factor 2	Homo sapiens	0-4	
35466502-11	2022	Conversely, Nrf2-overexpressing HCC cells displayed resistance to lenvatinib and low lipid ROS levels.	lenvatinib	66-76	NFE2 like bZIP transcription factor 2	Homo sapiens	12-16	
35466502-14	2022	Nrf2 is involvedin the sensitivity of HCC to lenvatinib.	lenvatinib	45-55	NFE2 like bZIP transcription factor 2	Homo sapiens	0-4	
31903165-10	2019	Taken together, our data indicate that deregulation of the KEAP1/Nrf2 pathway following KEAP1 inactivation contributes to sorafenib, lenvatinib, and regorafenib resistance in human HCC cells through up-regulation of Nrf2 downstream genes and decreased ROS levels.	lenvatinib	133-143	NFE2 like bZIP transcription factor 2	Homo sapiens	65-69